|1.||Tribouilloy, Christophe: 10 articles (02/2015 - 08/2010)|
|2.||Jobic, Yannick: 10 articles (02/2015 - 01/2010)|
|3.||Ennezat, Pierre-Vladimir: 8 articles (04/2015 - 12/2012)|
|4.||Maréchaux, Sylvestre: 7 articles (02/2015 - 04/2011)|
|5.||Bruneval, Patrick: 6 articles (04/2015 - 03/2012)|
|6.||Rusinaru, Dan: 6 articles (02/2015 - 08/2010)|
|7.||Etienne, Yves: 5 articles (12/2014 - 01/2010)|
|8.||Jeu, Antoine: 4 articles (02/2015 - 11/2011)|
|9.||Andréjak, Michel: 4 articles (12/2013 - 08/2010)|
|10.||Frachon, Irène: 4 articles (04/2013 - 01/2010)|
01/01/1999 - "It has been reported that benfluorex ameliorates the insulin resistance induced by high-fat feeding when its administration is initiated at the same time as the change in diet. "
03/01/2006 - "Significant between-group differences in favor of benfluorex were observed for mean FPG (-1.65 mmol/l) (P < 0.001) and for homeostasis model assessment of insulin resistance. "
08/01/1999 - "The treatment of insulin resistance was for a long time limited to dietary and exercise programmes, a biguanide, metformine, and benfluorex, a phenylethylamine derivative; the mechanisms of action of both drugs are now better understood and their indications more precisely targeted. "
01/01/1999 - "Here we have examined whether benfluorex reverses insulin resistance when this is established in middle-aged rats chronically maintained on a high-fat diet. "
11/01/1993 - "Benfluorex decreases insulin resistance and improves lipid profiles in obese type 2 diabetic patients."
|2.||Type 2 Diabetes Mellitus (MODY)
01/01/2012 - "Echocardiographic evidence for valvular toxicity of benfluorex: a double-blind randomised trial in patients with type 2 diabetes mellitus."
06/01/1989 - "In NIDDM patients treated with benfluorex, normalisation of basal blood glucose levels was accompanied by an improvement in the OGTT blood glucose curve which was statistically significant relative to Group B. "
01/01/2012 - "REGULATE trial was designed to compare the efficacy and safety of benfluorex versus pioglitazone in type 2 diabetes mellitus (DM) patients. "
05/01/2011 - "Benfluorex is a fenfluramine derivative approved for the treatment of metabolic syndrome and type 2 diabetes mellitus. "
02/01/1991 - "We evaluate fasting glucose production (3H-glucose infusion) and B-cell secretion (phi 1, phi 2 and glucose utilization SI) (minimal model technique) in 7 mild, diet treated, NIDDM patients after 6-week administration of benfluorex (450 mg/day) and placebo, in random sequence and double blind design. "
09/01/1977 - "The effects of benfluramate on carbohydrate metabolism in obesity."
09/09/1992 - "These studies confirm that, in an animal model of obesity associated with insulin resistance, benfluorex exerts a marked hypolipidemic effect and improves insulin resistance. "
09/01/1997 - "Adjunct treatments comprise a few pharmacological approaches which may help to improve glycaemic control by correcting some abnormalities frequently associated with NIDDM, such as obesity (serotoninergic anorectic agents) and hyperlipidaemia (benfluorex). "
07/25/1997 - "Benfluorex has both anorectic and metabolic effects that lower body weight and improve insulin sensitivity in obesity and type 2 diabetes. "
09/01/1996 - "In type II diabetics with mild obesity and hyperglycemia previously managed with diet alone, benfluorex has significant long-term effect on HbA1c and mean daily blood glucose, and tends to lower insulinemia."
|4.||Body Weight (Weight, Body)
09/01/1996 - "At the end of the study, the groups did not differ in body weight or BMI; however, HbA1c decreased more with benfluorex (6.0 +/- 1.0% versus 6.8 +/- 0.9%, p = 0.024), as did the mean glycemic profile (7.8 +/- 1.4 versus 8.5 +/- 1.7 mmol/L, p < 0.001), including a particular decrease in postprandial glycemia. "
08/01/1996 - "Pair-fed rats showed body weights virtually identical with those of benfluorex-treated animals. "
08/01/1996 - "Benfluorex at 35-40 mg.kg-1 body weight was administered in the food from 10 to 14 weeks of age and resulted in an initial 50% decrease in food consumption. "
08/20/1991 - "Rats of the JCR:LA-corpulent strain were treated with benfluorex daily at a dose of 25 mg/kg body weight. "
02/01/1998 - "Addition of benfluorex in obese insulin-requiring Type 2 diabetes thus enhances glycaemic control and lowers both daily insulin requirement and body weight. "
02/01/2004 - "(3) Benfluorex is sold in France as an adjunctive treatment for hypertriglyceridemia and diabetes with overweight. "
01/01/1998 - "[Benfluorex (Mediator): non-insulin-dependent diabetes and hypertriglyceridemia]."
09/01/2011 - "As compared with the 'no ASD' group (n= 12), patients in the benfluorex group (n= 34) were more frequently female, had more frequent arterial hypertension and hypertriglyceridemia, and presented more frequently with combined mitral and aortic disease (79 vs. 8%, P < 0.001). "
03/01/2011 - "Benfluorex, an amphetamine derivative, was marketed as an adjunctive drug for patients with hypertriglyceridemia or diabetes with overweight. "
08/20/1991 - "The changes produced by benfluorex are all in directions that should inhibit atherogenesis in this animal model for the human obesity/hypertriglyceridemia/insulin resistant syndrome."
|2.||Blood Glucose (Blood Sugar)
|5.||Appetite Depressants (Anorectics)
|6.||Uric Acid (Urate)
|10.||Idiopathic pulmonary hypertension